Cargando…

Initial Clinical Experience with AZD5718, a Novel Once Daily Oral 5‐Lipoxygenase Activating Protein Inhibitor

We evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD5718, a novel 5‐lipooxygenase activating protein (FLAP) inhibitor, in a randomized, single‐blind, placebo‐controlled, first‐in‐human (FIH) study consisting of single and multiple ascending dosing (SAD and MAD) for 10 day...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ericsson, Hans, Nelander, Karin, Lagerstrom‐Fermer, Maria, Balendran, Clare, Bhat, Maria, Chialda, Ligia, Gan, Li‐Ming, Heijer, Maria, Kjaer, Magnus, Lambert, John, Lindstedt, Eva‐Lotte, Forsberg, Gun‐Britt, Whatling, Carl, Skrtic, Stanko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944575/ https://www.ncbi.nlm.nih.gov/pubmed/29517132 http://dx.doi.org/10.1111/cts.12546

Ejemplares similares

Phase 1 Pharmacokinetic Study of AZD5718 in Healthy Volunteers: Effects of Coadministration With Rosuvastatin, Formulation and Food on Oral Bioavailability
por: Ericsson, Hans, et al.
Publicado: (2019)

Pharmacokinetics, Pharmacodynamics, and Tolerability of AZD5718, an Oral 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor, in Healthy Japanese Male Subjects
por: Knöchel, Jane, et al.
Publicado: (2021)

Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo‐controlled, phase I study in healthy volunteers
por: Gan, Li‐Ming, et al.
Publicado: (2019)

Design of FLAIR: a Phase 2b Study of the 5-Lipoxygenase Activating Protein Inhibitor AZD5718 in Patients With Proteinuric CKD
por: Heerspink, Hiddo J.L., et al.
Publicado: (2021)

Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction
por: Nelander, Karin, et al.
Publicado: (2021)

Design and rationale of FLAVOUR: A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarction
por: Prescott, Eva, et al.
Publicado: (2020)

Pharmacokinetic Profile of Lesogaberan (AZD3355) in Healthy Subjects: A Novel GABA(B)-Receptor Agonist Reflux Inhibitor
por: Niazi, Mohammad, et al.
Publicado: (2012)

Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes
por: Gan, Li-Ming, et al.
Publicado: (2019)

Achieving a physiological cortisol profile with once-daily dual-release hydrocortisone: a pharmacokinetic study
por: Johannsson, Gudmundur, et al.
Publicado: (2016)

Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study
por: Whittaker, Andrew, et al.
Publicado: (2019)

Dipeptidyl Peptidase 1 Inhibitor AZD7986 Induces a Sustained, Exposure‐Dependent Reduction in Neutrophil Elastase Activity in Healthy Subjects
por: Palmér, Robert, et al.
Publicado: (2018)

Long-term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency: a phase 3b, open-label, extension study
por: Nilsson, Anna G, et al.
Publicado: (2017)

Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction
por: Inghardt, Tord, et al.
Publicado: (2022)

Synthetic mRNA Encoding VEGF-A in Patients Undergoing Coronary Artery Bypass Grafting: Design of a Phase 2a Clinical Trial
por: Anttila, Vesa, et al.
Publicado: (2020)

Low background and high contrast PET imaging of amyloid-β with [(11)C]AZD2995 and [(11)C]AZD2184 in Alzheimer’s disease patients
por: Forsberg, Anton, et al.
Publicado: (2013)

Correction to “Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction”
por: Inghardt, Tord, et al.
Publicado: (2022)

Inhibitors of mitogen-activated protein kinases differentially regulate costimulated T cell cytokine production and mouse airway eosinophilia
por: Chialda, Ligia, et al.
Publicado: (2005)

Toward molecular imaging of the free fatty acid receptor 1
por: Hellström-Lindahl, Ewa, et al.
Publicado: (2017)

4-Aminobutyrate Aminotransferase (ABAT): Genetic and Pharmacological Evidence for an Involvement in Gastro Esophageal Reflux Disease
por: Jirholt, Johan, et al.
Publicado: (2011)

Lipoxygenases—Killers against Their Will?
por: Friedmann Angeli, José Pedro, et al.
Publicado: (2018)

Avenanthramides as lipoxygenase inhibitors
por: Landberg, Rikard, et al.
Publicado: (2020)

Exploring the insulin secretory properties of the PGD(2)-GPR44/DP2 axis in vitro and in a randomized phase-1 trial of type 2 diabetes patients
por: Skrtic, Stanko, et al.
Publicado: (2018)

Expression of 5-lipoxygenase and 15-lipoxygenase in rheumatoid arthritis synovium and effects of intraarticular glucocorticoids
por: Gheorghe, Karina Roxana, et al.
Publicado: (2009)

Secretagogin is increased in plasma from type 2 diabetes patients and potentially reflects stress and islet dysfunction
por: Hansson, Sara F., et al.
Publicado: (2018)

Lipoxygenase Inhibition by Plant Extracts
por: Lončarić, Melita, et al.
Publicado: (2021)

Collagen type III alpha I is a gastro-oesophageal reflux disease susceptibility gene and a male risk factor for hiatus hernia
por: Åsling, B, et al.
Publicado: (2009)

5-lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes
Publicado: (1993)

Contemporary risk estimates of three HbA(1c) variables in relation to heart failure following diagnosis of type 2 diabetes
por: Skrtic, Stanko, et al.
Publicado: (2017)

Participation of 5-lipoxygenase and LTB4 in liver regeneration after partial hepatectomy
por: Lorenzetti, Florencia, et al.
Publicado: (2019)

Discovery of α-Linolenic Acid 16(S)-Lipoxygenase: Cucumber (Cucumis sativus L.) Vegetative Lipoxygenase 3
por: Gorina, Svetlana S., et al.
Publicado: (2023)

Recombinant Soybean Lipoxygenase 2 (GmLOX2) Acts Primarily as a ω6(S)-Lipoxygenase
por: Smirnova, Elena O., et al.
Publicado: (2023)

Inhibition of tumour growth by lipoxygenase inhibitors.
por: Hussey, H. J., et al.
Publicado: (1996)

Hydrogen Tunneling in a Prokaryotic Lipoxygenase
por: Carr, Cody A. Marcus, et al.
Publicado: (2014)

The Lipoxygenases: Their Regulation and Implication in Alzheimer’s Disease
por: Czapski, Grzegorz A., et al.
Publicado: (2015)

Regulation of Tissue Inflammation by 12-Lipoxygenases
por: Kulkarni, Abhishek, et al.
Publicado: (2021)

Data on expression of lipoxygenases-5 and -12 in the normal and acetaminophen-damaged liver
por: Suciu, Maria, et al.
Publicado: (2016)

Oestrogen receptor α gene haplotype and postmenopausal breast cancer risk: a case control study
por: Wedrén, Sara, et al.
Publicado: (2004)

rs953413 Regulates Polyunsaturated Fatty Acid Metabolism by Modulating ELOVL2 Expression
por: Pan, Gang, et al.
Publicado: (2020)

Evaluation of AZD1446 as a Therapeutic in DYT1 Dystonia
por: Zimmerman, Chelsea N., et al.
Publicado: (2017)

Prothrombin time is predictive of low plasma prothrombin concentration and clinical outcome in patients with trauma hemorrhage: analyses of prospective observational cohort studies
por: Balendran, Clare A., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_mgs0thea8k5281ql613t2bvicc